Even though the advent of CDK4/6i has dramatically improved the outcomes of patients with HR+/HER2− advanced breast cancer, about 20% of patients do not benefit from this therapy and may require different approaches upfront [2,3,4,5,6,7]. This evidence concerns the gene CDK4 and breast cancer.